{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:11:38Z","timestamp":1788970298680,"version":"build-2803163510"},"reference-count":31,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Treatment options for relapsed and refractory acute myeloid leukemia patients (R\/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) without or with venetoclax (FLAVIDA) in patients with R\/R AML. Thirty-seven and 81 patients received one course FLA-IDA with or without a 7-day course of venetoclax, respectively. The overall response rate (ORR) was significantly higher in FLAVIDA compared to FLAIDA- treated patients (78% vs. 47%; P=0.001), while measurable residual disease was negative at a similar proportion in responding patients (50% vs. 57%), respectively. Eighty-one percent and 79% of patients proceeded to allogeneic hematopoietic cell transplantation or donor lymphocyte infusion after FLAVIDA and FLA-IDA, respectively. Event-free and overall survival were similar in FLAVIDA- and FLA-IDA-treated patients. Refractory patients could be salvaged more successfully after FLA-IDA compared to FLAVIDA pretreatment. Neutrophil and platelet recovery times were similar in the venetoclax and the control group. In conclusion, short-term venetoclax in combination with FLA-IDA represents an effective treatment regimen in R\/R AML identifying chemosensitive patients rapidly and inducing measurable residual disease-negative remission in a high proportion of R\/R AML patients.<\/jats:p>","DOI":"10.3324\/haematol.2023.282912","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T03:45:09Z","timestamp":1689824709000},"page":"72-83","source":"Crossref","is-referenced-by-count":8,"title":["Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Rabia","family":"Shahswar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razif","family":"Gabdoulline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Kloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Gohring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Lisa","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa-Kristin","family":"Dallmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piroska","family":"Klement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherin","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Alwie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Saadati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"55936","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"55937","doi-asserted-by":"crossref","unstructured":"Walter RB, Othus M, Burnett AK. Resistance prediction in AML: analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015; 29(2):312-320.","DOI":"10.1038\/leu.2014.242"},{"key":"55938","doi-asserted-by":"crossref","unstructured":"Heuser M, Ofran Y, Boissel N. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2021;32(6):821]. Ann Oncol. 2020; 31(6):697-712.","DOI":"10.1016\/j.annonc.2020.02.018"},{"key":"55939","doi-asserted-by":"crossref","unstructured":"Thol F, Heuser M. Treatment for relapsed\/refractory cute myeloid leukemia. Hemasphere. 2021; 5(6):e572.","DOI":"10.1097\/HS9.0000000000000572"},{"key":"55940","doi-asserted-by":"crossref","unstructured":"Nath R, Reddy V, Kapur A. Survival of relapsed\/refractory acute myeloid leukemia (R\/R AML) patients receiving stem cell transplantation (SCT). Biol Blood Marrow Transplant. 2019; 25(3).","DOI":"10.1016\/j.bbmt.2018.12.407"},{"key":"55941","doi-asserted-by":"crossref","unstructured":"Westhus J, Noppeney R, D\u00fchrsen U, Hanoun M. FLAG salvage therapy combined with idarubicin in relapsed\/refractory acute myeloid leukemia. Leuk Lymphoma. 2019; 60(4):1014-1022.","DOI":"10.1080\/10428194.2018.1508670"},{"key":"55942","doi-asserted-by":"crossref","unstructured":"Marconi G, Talami A, Abbenante MC. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. Eur J Haematol. 2020; 105(1):47-55.","DOI":"10.1111\/ejh.13406"},{"key":"55943","doi-asserted-by":"crossref","unstructured":"Canaani J, Nagar M, Heering G. Reassessing the role of high dose cytarabine and mitoxantrone in relapsed\/refractory acute myeloid leukemia. Oncotarget. 2020; 11(23):2233-2245.","DOI":"10.18632\/oncotarget.27618"},{"key":"55944","doi-asserted-by":"crossref","unstructured":"Meg\u00edas-Vericat JE, Mart\u00ednez-Cuadr\u00f3n D, Sanz M\u00c1, Montesinos P. Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018; 97(7):1115-1153.","DOI":"10.1007\/s00277-018-3304-y"},{"key":"55945","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"55946","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Maiti A, Rausch CR. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020; 7(10):e724-36.","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"55947","doi-asserted-by":"crossref","unstructured":"Wei AH, Montesinos P, Ivanov V. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020; 135(24):2137-2145.","DOI":"10.1182\/blood.2020004856"},{"key":"55948","doi-asserted-by":"crossref","unstructured":"Lachowiez CA, Loghavi S, Kadia TM. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020; 4(7):1311-1320.","DOI":"10.1182\/bloodadvances.2019001267"},{"key":"55949","doi-asserted-by":"crossref","unstructured":"Konopleva M, Thirman MJ, Pratz KW. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia. Clin Cancer Res. 2022; 28(13):2744-2752.","DOI":"10.1158\/1078-0432.CCR-21-3405"},{"key":"55950","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Pratz KW, Wei AH. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res. 2022; 28(24):5272-5279.","DOI":"10.1158\/1078-0432.CCR-22-1183"},{"key":"55951","doi-asserted-by":"crossref","unstructured":"Chua CC, Roberts AW, Reynolds J. Chemotherapy and venetoclax in elderly acute myeloid leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020; 38(30):3506-3517.","DOI":"10.1200\/JCO.20.00572"},{"key":"55952","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021; 39(25):2768-2778.","DOI":"10.1200\/JCO.20.03736"},{"key":"55953","doi-asserted-by":"crossref","unstructured":"Lachowiez CA, Reville PK, Kantarjian H. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022; 9(5):e350-e360.","DOI":"10.1016\/S2352-3026(22)00076-X"},{"key":"55954","doi-asserted-by":"crossref","unstructured":"Wolach O, Frisch A, Shargian L. Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. Ann Hematol. 2022; 101(8):1719-1726.","DOI":"10.1007\/s00277-022-04883-y"},{"key":"55955","doi-asserted-by":"crossref","unstructured":"Zucenka A, Vaitekenaite V, Maneikis K. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021; 56(11):2804-2812.","DOI":"10.1038\/s41409-021-01416-5"},{"key":"55956","doi-asserted-by":"crossref","unstructured":"Shahswar R, Beutel G, Klement P. FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed\/refractory acute leukaemia. Br J Haematol. 2020; 188(3):e11-e15.","DOI":"10.1111\/bjh.16268"},{"key":"55957","doi-asserted-by":"crossref","unstructured":"Heuser M, Gabdoulline R, L\u00f6ffeld P. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol. 2017; 96(8):1361-1372.","DOI":"10.1007\/s00277-017-3027-5"},{"key":"55958","doi-asserted-by":"crossref","unstructured":"Gabert J, Beillard E, van der Velden VHJ. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program. Leukemia. 2003; 17(12):2318-2357.","DOI":"10.1038\/sj.leu.2403135"},{"key":"55959","doi-asserted-by":"crossref","unstructured":"Thol F, Gabdoulline R, Liebich A. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018; 132(16):1703-1713.","DOI":"10.1182\/blood-2018-02-829911"},{"key":"55960","doi-asserted-by":"crossref","unstructured":"Kr\u00f6nke J, Schlenk RF, Jensen K-O. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011; 29(19):2709-2716.","DOI":"10.1200\/JCO.2011.35.0371"},{"key":"55961","doi-asserted-by":"crossref","unstructured":"Schuurhuis GJ, Heuser M, Freeman S. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12):1275-1291.","DOI":"10.1182\/blood-2017-09-801498"},{"key":"55962","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"55963","doi-asserted-by":"crossref","unstructured":"Bergua JM, Montesinos P, Martinez-Cuadr\u00f3n D. A prognostic model for survival after salvage treatment with FLAG-Ida +\/- gemtuzumab-ozogamicine in adult patients with refractory\/relapsed acute myeloid leukaemia. Br J Haematol. 2016; 174(5):700-710.","DOI":"10.1111\/bjh.14107"},{"key":"55964","doi-asserted-by":"crossref","unstructured":"Roboz GJ, Rosenblat T, Arellano M. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2014; 32(18):1919-1926.","DOI":"10.1200\/JCO.2013.52.8562"},{"key":"55965","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"55966","doi-asserted-by":"crossref","unstructured":"Maiti A, Rausch CR, Cortes JE. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021; 106(3):894-898.","DOI":"10.3324\/haematol.2020.252569"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282912\/75840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282912\/76418","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282912\/75840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:25:26Z","timestamp":1788967526000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282912","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}